Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Non-Current Liabilities (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Total Non-Current Liabilities readings, the most recent being $671.4 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 15.0% to $671.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $671.4 million, a 15.0% increase, with the full-year FY2025 number at $671.4 million, up 15.0% from a year prior.
  • Total Non-Current Liabilities hit $671.4 million in Q4 2025 for Amicus Therapeutics, up from $638.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $671.4 million in Q4 2025 to a low of $532.8 million in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $598.3 million (2023), compared with a mean of $597.0 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 72.59% in 2021 and later dropped 5.46% in 2024.
  • Amicus Therapeutics' Total Non-Current Liabilities stood at $577.4 million in 2021, then rose by 0.39% to $579.7 million in 2022, then rose by 6.54% to $617.6 million in 2023, then decreased by 5.46% to $583.9 million in 2024, then grew by 15.0% to $671.4 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $671.4 million (Q4 2025), $638.4 million (Q3 2025), and $611.0 million (Q2 2025) per Business Quant data.